HC Wainwright Raises AngioDynamics (NASDAQ:ANGO) Price Target to $15.00

AngioDynamics (NASDAQ:ANGO) had its target price raised by equities researchers at HC Wainwright from $14.00 to $15.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the medical instruments supplier’s stock. HC Wainwright’s price objective would indicate a potential upside of 15.92% from the company’s previous close.

Separately, Canaccord Genuity Group lowered their price target on AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a report on Friday, October 4th.

AngioDynamics Stock Up 37.7 %

NASDAQ ANGO opened at $12.94 on Friday. AngioDynamics has a 52 week low of $5.26 and a 52 week high of $13.13. The company has a 50 day moving average price of $8.12 and a 200 day moving average price of $7.38. The firm has a market cap of $525.80 million, a PE ratio of -2.12 and a beta of 0.59.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 5.86% and a negative net margin of 83.95%. The business had revenue of $72.90 million for the quarter, compared to the consensus estimate of $70.93 million. During the same period in the prior year, the firm posted ($0.05) earnings per share. The business’s quarterly revenue was down .1% on a year-over-year basis. On average, equities research analysts anticipate that AngioDynamics will post -0.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On AngioDynamics

A number of large investors have recently made changes to their positions in the stock. Quarry LP raised its stake in AngioDynamics by 75.1% in the 2nd quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier’s stock worth $37,000 after acquiring an additional 2,594 shares during the last quarter. CWM LLC increased its holdings in shares of AngioDynamics by 981.3% in the third quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier’s stock valued at $76,000 after purchasing an additional 8,832 shares during the period. Mackenzie Financial Corp purchased a new position in shares of AngioDynamics in the second quarter worth about $80,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of AngioDynamics during the third quarter worth about $86,000. Finally, AE Wealth Management LLC purchased a new stake in AngioDynamics in the second quarter valued at approximately $87,000. 89.43% of the stock is owned by hedge funds and other institutional investors.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.